Trial · NCT03703375
Adverse events1,168
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 1,168
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leukopenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Gemcitabine: 1000 mg/m2 | 3 | 3 | |
| other | Leukopenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Gemcitabine: 1200 mg/m2 | 1 | 20 | |
| other | Leukopenia | Blood and lymphatic system disorders | Safety Run-in Oral Azacitidine: 100 mg | 1 | 3 | |
| other | Leukopenia | Blood and lymphatic system disorders | Safety Run-in Oral Azacitidine: 200 mg | 1 | 3 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Oral Azacitidine: 200 mg | 5 | 8 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Oral Azacitidine: 300 mg | 15 | 34 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Romidepsin | 3 | 4 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Bendamustine | 14 | 16 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Gemcitabine: 1000 mg/m2 | 3 | 3 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Gemcitabine: 1200 mg/m2 | 15 | 20 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Safety Run-in Oral Azacitidine: 100 mg | 0 | 3 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Safety Run-in Oral Azacitidine: 200 mg | 2 | 3 | |
| other | Neutropenia | Blood and lymphatic system disorders | Oral Azacitidine: 200 mg | 3 | 8 | |
| other | Neutropenia | Blood and lymphatic system disorders | Oral Azacitidine: 300 mg | 15 | 34 | |
| other | Neutropenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Romidepsin | 3 | 4 | |
| other | Neutropenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Bendamustine | 9 | 16 | |
| other | Neutropenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Gemcitabine: 1000 mg/m2 | 2 | 3 | |
| other | Neutropenia | Blood and lymphatic system disorders | Investigators Choice Therapy - Gemcitabine: 1200 mg/m2 | 11 | 20 | |
| other | Neutropenia | Blood and lymphatic system disorders | Safety Run-in Oral Azacitidine: 100 mg | 1 | 3 | |
| other | Neutropenia | Blood and lymphatic system disorders | Safety Run-in Oral Azacitidine: 200 mg | 2 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03703375/events?page=2